It has not been possible to determine which symptoms are due to carnitine deficiency and which are due to an underlying organic acidemia, as symptoms of both abnormalities may be expected to improve with levocarnitine (injection)
Weight loss in diabetes trials is typically more modest
Due to the active metabolism of neurons, the demand for oxygen is high and a large number of ROS are produced
In a large phase 3 obesity trial (ACHIEVE-1), orforglipron at daily doses of 3, 12 and 36 mg caused approximately: Diarrhoea: 1926% of participants (vs 9% on placebo) Nausea: 1318% (vs 2% on placebo) Constipation: 817% (vs 4% on placebo) Vomiting: 514% (vs 1% on placebo) Across multiple studies, 617% of people stopped treatment because of side effects, mostly gut-related symptoms
The GI effects of retatrutide, particularly nausea and reduced appetite, can make it harder to maintain the caloric and protein intake needed to support tissue repair processes